| Literature DB >> 29594116 |
Dirlei Nico1, Luciana Conde1, Juan L Rivera-Correa2, Andréia Vasconcelos-Dos-Santos3, Louise Mesentier-Louro3, Leonardo Freire-de-Lima3, Mônica Barcellos Arruda4, Celio Geraldo Freire-de-Lima3, Orlando da Costa Ferreira4, Maria Elisabeth Lopes Moreira5, Andrea Araújo Zin5, Zilton Farias Meira Vasconcelos5, Rosalia Mendez Otero3, Clarisa Beatriz Palatnik-de-Sousa1, Amilcar Tanuri4, Adriane Regina Todeschini3, Wilson Savino6,7, Ana Rodriguez2, Alexandre Morrot8,9.
Abstract
Zika virus (ZIKV) disease has become a global health emergency with devastating effects on public health. Recent evidences implicate the virus as an emergent neuropathological agent promoting serious pathologies of the human nervous system, that include destructive and malformation consequences such as development of ocular and fetal brain lesions, microcephaly in neonates, and Guillain-Barré syndrome (GBS) in adults. These neurological disorders of both central and peripheral nervous systems are thought to be associated to the neurotropic properties of the virus that has ability to infect neural stem cells as well as peripheral neurons, a hallmark of its pathogenicity. The presence of autoantibodies against gangliosides plays a pivotal role in the etiogenesis of GBS and a variety of neurological disorders. Gangliosides are a class of galactose-containing cerebrosides mainly expressed in nervous system tissues playing a critical role in the physiology of neural cells and neurogenesis. Herein, our findings indicate that patients at acute phase of ZIKV infection without any neurological signs show increased levels of IgG autoantibody against GD3 gangliosides, a class of glycolipid found to be highly expressed in neural stem cell acting in the maintenance of their self-renewal cellular capacity. It is possible that a pathological threshold of these antibodies is only acquired in secondary or subsequent infections. In the light of these evidences, we propose that the target of GD3 by autoimmune responses may possibly has an effect in the neuropathy and neurogenesis disorder seen during ZIKV infection.Entities:
Keywords: Zika virus; autoantibody; autoimmunity; gangliosides; infectious diseases
Year: 2018 PMID: 29594116 PMCID: PMC5854646 DOI: 10.3389/fmed.2018.00025
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Clinical data of adult Zika patients whose serum samples were included in the study.
| Samples | Gender | Symptoms onset (date) | Zyka PCR | Zika exposure |
|---|---|---|---|---|
| A#1 | M | 02/21/2016 | + | Y |
| A#2 | M | 03/10/2016 | + | Y |
| A#3 | F | Unknown | + | Y |
| A#4 | M | 03/25/2016 | + | Y |
| A#5 | F | 02/05/2016 | + | Y |
| A#6 | M | Unknown | + | Y |
| A#7 | F | 04/17/2016 | + | Y |
| A#8 | F | 04/27/2016 | + | Y |
| A#9 | F | 04/25/2016 | + | Y |
| A#10 | F | 05/01/2016 | + | Y |
| A#11 | F | 05/03/2016 | + | Y |
| A#12 | M | Unknown | + | Y |
| A#13 | M | Unknown | + | Y |
Clinical data of pregnant patients with Zika infection whose serum samples were included in the study.
| Samples | Pregnancy period (symptoms onset) | Gestacional age (weeks) | Zyka PCR | Zyka serology (IgM) | Zika exposure |
|---|---|---|---|---|---|
| P#1 | 3rd trimester | 38 | + | Not done | Y |
| P#2 | 1st trimester | 39 | + | Not done | Y |
| P#3 | 1st trimester | 38 | − | + | Y |
| P#4 | 1st trimester | 41 | + | Not done | Y |
| P#5 | 1st trimester | 39 | + | Not done | Y |
| P#6 | 3rd trimester | 38 | + | Not done | Y |
| P#7 | 2nd trimester | 38 | − | + | Y |
| P#8 | 1st trimester | 40 | + | Not done | Y |
| P#9 | 3rd trimester | 40 | + | Not done | Y |
| P#10 | 2nd trimester | 38 | + | Not done | Y |
| P#11 | 1st trimester | 39 | + | Not done | Y |
| P#12 | 2nd trimester | 38 | − | + | Y |
Figure 1Autoantibody levels to gangliosides in Zika-infected patients and healthy control individuals. ELISA plates coated with the indicated gangliosides at 20 µg/ml in ethanol, followed by evaporation, were incubated with 1:100 dilution of sera from Zika patients or control healthy individuals and developed with anti-total IgG or anti-Ig-specific subclasses conjugated to HRP. Scatter plots show individual values for each Zika-infected patient (n = 13) and healthy individual (n = 17) for recognition of (A,C) IgG class autoantibodies and (B,D) IgG subclasses (IgG1, IgG2, IgG3, and IgG4 isotypes), against (A,B) total gangliosides (from bovine brain extract) or (C,D) purified ganglioside GD3. Each data point is the mean of triplicated determinations. Means of data points for each individual ± SE are shown. Differences between groups are significant *(p ≤ 0.05), **(p ≤ 0.01), ***(p ≤ 0.01).
Figure 2Autoantibody profile in Zika-infected patients recognizing GD3 gangliosides from retinal tissue. Retinal sections obtained from wild-type and GD3-deficient mice were stained with control antibody (CD60b, red) to detect the 9-O-acetylated form of GD3 ganglioside. Serum derived from Zika patients (A,C,E) recognized antigens (green) in the wild-type retina, more abundantly in the inner nuclear layer (arrows). Control healthy serum (B,D,F) did not recognize antigens in the outer and inner nuclear layers in which GD3 is largely expressed. A level of serum reactivity for the ganglion cell layer was noticed in wild-type sections exposed to both human sera groups. Images are merged with nuclei (TOPRO, blue).
Figure 3Increased levels of IgG4 autoantibody against to GD3 ganglioside in Zika virus infection during pregnancy. ELISA plates coated with GD3 ganglioside (20 µg/ml) were incubated with 1:100 dilution of sera from pregnant patients with Zika infection or control healthy pregnant individuals. The sera was obtained after pregnancy, and the reaction was developed with (A) anti-total IgG or (B) anti-Ig-specific subclasses conjugated to HRP. Scatter plots show individual values for each Zika-infected patient (n = 12) and healthy individual (n = 8). Means of data points for each individual ± SE are shown. Differences between groups are significant *(p ≤ 0.05).